Company intelligence / Profile preview
OsteoCure Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
OsteoCure’s lead product—a multifunctional, injectable hydrogel—has demonstrated accelerated bone repair and reduced pain in healthy and impaired healing animal models. The technology leverages local delivery of naturally occurring small molecules like adenosine to promote osteogenesis, inhibit fat formation, increase angiogenesis, and provide analgesia. The company is advancing toward larger animal studies as a precursor to human clinical trials.
- Therapeutic areas
- OtherRheumatology
- Modalities
- Small moleculeInjectable hydrogel-based drug delivery therapy (injectable system delivering small molecules such as adenosine)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on OsteoCure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OsteoCure Therapeutics.